Related Experiment Video
Updated: Aug 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Anticoagulation in cardiac pathologies (except atrial fibrillation)]
1Département de Cardiologie, C.H.U. Tivoli, La Louvière, U.L.B.
Insights
Anticoagulant therapies, like heparins and antivitamins K, are crucial in cardiology. New uses are emerging, but careful benefit-risk assessment is vital for conditions like valvular prosthesis and dilated cardiomyopathy.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Anticoagulants, including heparins and vitamin K antagonists, are widely used in cardiovascular medicine.
- Established treatment guidelines exist, but new indications are continually emerging.
- The role of anticoagulation in various cardiac conditions requires ongoing evaluation.
Purpose:
- To review current and emerging indications for anticoagulant therapy in cardiology.
- To emphasize the importance of benefit-risk assessment in prescribing anticoagulants.
- To provide guidance on anticoagulant use in specific cardiac conditions.
Summary:
- Oral anticoagulants significantly reduce thromboembolic risk in patients with cardiac valvular prostheses.
- For non-operated valvulopathy, anticoagulant indication requires individualized benefit-risk evaluation.
- Anticoagulant prescription in dilated cardiomyopathy should be restricted to high-embolic-risk patients.
- Indications beyond atrial fibrillation necessitate careful consideration.
Impact:
- Informs clinical decision-making regarding anticoagulant use in complex cardiac cases.
- Highlights the need for personalized medicine approaches in cardiovascular pharmacotherapy.
- Contributes to optimizing patient outcomes by managing thromboembolic risks effectively.
Abstract:
Anticoagulants, including heparins and antivitamins K are medicines which are largely prescribed in cardiology. Even though the outlines of the treatment have been clearly established for a few decades, new cardiological indications have recently appeared. The long-term treatment of cardiac valvular prosthesis by oral anticoagulants significantly reduces the risk of thrombo-embolic incident among people carrying a cardiac valvular prosthesis. In case of non-operated valvulopathy, treatment indication must be evaluated for each patient; in so doing, the connection benefit/risk must always be taken into account. In case of dilated cardiomyopathy, the treatment prescription must be limited to the patients with a high embolic risk. Other cardiological indications (apart from atrial fibrillation) must be carefully weighed up.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Cardiac Catheterization I: Pre-Procedure Overview
Dysrhythmias VI: Management of Dysrhythmias
Cardiomyopathy V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

